Optimistic Buy Rating for Aquestive Therapeutics Driven by Anaphylm NDA Submission and Strong Financial Position

Analyst Roanna Ruiz from Leerink Partners maintained a Buy rating on Aquestive Therapeutics (AQST – Research Report) and decreased the price target to $12.00 from $13.00.

Roanna Ruiz has given her Buy rating due to a combination of factors related to Aquestive Therapeutics’ recent developments and financial outlook. The company has initiated the NDA submission for Anaphylm, a promising no-needle epinephrine option for Type 1 allergy and anaphylaxis, which could potentially enhance their market position if approved. The management’s confirmation that the pediatric trial results met expectations adds confidence to the NDA filing process.
Additionally, Aquestive’s financial health, with a cash reserve of approximately $93 million, is expected to sustain operations into 2026, providing a stable foundation for future growth. The company’s openness to potential partnerships for Anaphylm also indicates strategic flexibility aimed at maximizing stakeholder value. These elements, coupled with the anticipated FDA review and potential AdCom, underpin Ruiz’s optimistic outlook on the stock.

Ruiz covers the Healthcare sector, focusing on stocks such as Lexicon Pharmaceuticals, Lantheus, and Aquestive Therapeutics. According to TipRanks, Ruiz has an average return of -12.2% and a 32.86% success rate on recommended stocks.

In another report released yesterday, H.C. Wainwright also reiterated a Buy rating on the stock with a $10.00 price target.